Full-year and Q4 2021 results Conference call and webcast for investors and analysts 10 February 2022 2 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things ...

AstraZeneca PLC (NASDAQ:AZN) Q4 2021 Earning Conference Call February 10, 2022 6:45 AM ET Company Participants Chris Sheldon - Head of Investor Relations Pascal Soriot - CEO & Executive Director Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Business Unit Susan Galbraith - EVP of Oncology Research & Development Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Menelas Pangalos - EVP of BioPharmaceuticals R&D Marc Dunoyer - CEO of A ...

AstraZeneca PLC (NASDAQ:AZN) Q2 2021 Earnings Conference Call July 29, 2021 6:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, BioPharmaceuticals Business Unit Marc Dunoyer - Executive Director and Chief Financial Officer Mene Pangalos - EVP, BioPharmaceuticals R&D Susan Galbraith - EVP, Oncology R&D Leon Wang - EVP, China and the Emerging Markets Aradhana Sarin - Chief Financial Officer elect Confe ...